Lucid Diagnostics Inc. (LUCD)
Nasdaq: LUCD · Surgical & Medical Instruments & Apparatus · New York, NY · filing with the SEC since 2020
Who owns Lucid Diagnostics Inc.
As filed with the SECHolders of 5% or more
1
PAVmed Inc. holds 27.5% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed Feb 9, 2026 says.
Directors and officers
12
report now, of 14 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
PAVmed Inc.
SCHEDULE 13D/A · filed Feb 9, 2026 · Common Stock, par value $0.001 per share · 28.3% in Oct 10, 2025
Ayrton Capital LLC
SCHEDULE 13G/A · filed Feb 13, 2025 · Common Stock, $0.001 par value · reported falling below 5%
What LUCD reports owning in othersstakes of 5% or more, and other ties
4 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 25, 2026.
Insider tradesForm 4
0sales
1purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$200,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 15 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Matheis Dennis | director | 0 | $0 | 0 | 1 | $200,000 |